Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib plus ICE chemotherapy in children and adolescents with relapsed/refractory solid tumors
KCT0003260Phase 2
Key facts
- Status
- Terminated
- Start
- Aug 2019
- Countries
- 1
- Sponsor
- Samsung Medical Center
- Modality
- Small Molecules
- Drugs
- pazopanib
- Conditions
- Nonhematologic neoplasmspediatric solid tumors
01
Overview
Phase 2, single-arm trial of pazopanib in Nonhematologic neoplasms and pediatric solid tumors, sponsored by Samsung Medical Center. Started Aug 2019; status: terminated.
02
Design
1 arm- Study design
- Non-randomizedSingle group
Pazopanib + ICE
Single treatment arm receiving pazopanib in combination with ICE chemotherapy for relapsed or refractory pediatric solid tumors.
03
Who it enrols
Children and adolescents with relapsed or refractory solid tumors; detailed inclusion and exclusion criteria were not provided.
Beyond the preview
Go deeper on KCT0003260.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0003260.